Marker Therapeutics IncMRKR
Price$1.05

Qualitative Analysis

Business overview

Business Overview

Marker Therapeutics, Inc. (Nasdaq: MRKR) is a clinical-stage immuno-oncology company headquartered in Houston, Texas. The company specializes in developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors. Its proprietary Multi-Antigen Recognizing (MAR)-T cell platform (formerly known as multiTAA-specific T cells) is a novel, non-genetically modified cell therapy approach. This technology selectively expands tumor-specific T cells from a patient's or donor's blood, enabling them to recognize a broad range of tumor antigens and target multiple tumor markers simultaneously to produce broad-spectrum anti-tumor activity.

Research as of 20 Jun 2026

Strategic Initiatives

Growth programs, investments, and their expected impact

AI-assisted
Clinical Prioritization of MT-601Innovation

Prioritizing the clinical advancement of lead Multi-Antigen Recognizing (MAR)-T cell therapy, MT-601, in patients with relapsed lymphoma (APOLLO study) and expanding into pancreatic cancer (PANACEA study).

Expected impact: Aims to establish proof-of-concept efficacy in heterogeneous tumors without genetic modification, reducing manufacturing costs and improving safety profiles.

Sign in / Sign up to read more
InvestmentSupported in part by non-dilutive grant funding, including a $9.5 million CPRIT grant and a $2 million NIH SBIR grant for the pancreatic cancer program.
TimelineOngoing through 2026, with dose expansion phase enrolling DLBCL patients at the maximum dose level.
Off-the-Shelf (OTS) Program ExpansionGrowth

Advancing MT-401 as an allogeneic, off-the-shelf product in the Phase 1 RAPID study for patients with AML or MDS to provide rapid treatment options.

Expected impact: Provides a fast-to-deliver treatment option for rapidly progressing hematological diseases, expanding the addressable patient population.

Sign in / Sign up to read more
InvestmentSupported by non-dilutive grant funds from the National Cancer Institute (NCI), FDA, and CPRIT.
TimelineFirst patient treated in late 2025; dose escalation and safety evaluations continuing through 2026.
Manufacturing Scale-Up and CDMO CollaborationEfficiency

Collaborating with Cellipont Bioservices for the technology transfer and cGMP manufacturing of MT-601 to support clinical scale-up and future commercial readiness.

Expected impact: Secures robust, high-quality clinical supply chain capabilities necessary to support potential pivotal trials and eventual commercialization.

Sign in / Sign up to read more
InvestmentFunded through existing cash resources and operational allocations.
TimelineTechnical transfer expected to be completed in Q2 2026.

Mergers, Acquisitions & Partnerships

Recent deals and strategic collaborations

AI-assisted

Strategic Partnerships

Cellipont BioservicesManufacturing Collaboration

Provides technology transfer and cGMP manufacturing services to scale up production of lead asset MT-601, laying the operational foundation for pivotal trials.

Terms: Terms of the agreement and subsequent statements of work were not publicly disclosed in detail.

Sign in / Sign up to read more
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.